Pasithea Therapeutics (KTTA) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 40.8% versus a loss of 84.8%. Radiopharm Theranostics is the larger company by market cap ($16.5 million vs $15.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KTTA | RADX |
|---|---|---|
| Share price | $0.4675 | $1.13 |
| Market cap | $15.62M | $16.49M |
| 1-day change | +6.03% | +1.80% |
| YTD return | -63.76% | -78.35% |
| 1-year return | -40.82% | -84.83% |
| 5-year return | -99.22% | — |
| EPS (TTM) | $-1.67 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.06 | $16.25 |
| 52-week low | $0.281 | $1.00 |
| Distance from 52-week high | -77.31% | -93.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +541.71% | +1403.54% |
| Average volume | 226.32K | 85.87K |
| Shares outstanding | 33.41M | 14.59M |
| Employees | 5 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed RADX by 44.0 percentage points over the past year.
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
KTTA vs RADX FAQ
Which is bigger, Pasithea Therapeutics or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $16.49M compared with $15.62M for Pasithea Therapeutics (KTTA).
Which stock has performed better over the past year, KTTA or RADX?
KTTA returned -40.82% over the past 12 months, compared with -84.83% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Pasithea Therapeutics and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.